FDA Approves Pirtobrutinib for Previously Treated CLL/SLL
The approval is the second this year for the reversible, highly selective kinase inhibitor following a January approval in mantle cell lymphoma.
Medscape Medical News
source https://www.medscape.com/viewarticle/fda-approves-pirtobrutinib-previously-treated-cll-sll-2023a1000u54?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/fda-approves-pirtobrutinib-previously-treated-cll-sll-2023a1000u54?src=rss
Comments
Post a Comment